Please login to the form below

Not currently logged in

Argos hit as kidney cancer immunotherapy fails phase III trial

Study discontinued as data shows renal cell carcinoma vaccine unlikely to meet targets

Argos TherapeuticsArgos Therapeutics' hopes of bringing lead cancer immunotherapy rocapuldencel-T to market anytime soon have been dashed after it flunked a pivotal phase III trial.

The independent data monitoring committee in the ADAPT study of the drug in patients with metastatic renal cell carcinoma (RCC) recommended that the trial be discontinued as there was little chance that Argos' drug would meet its targets.

Rocapuldencel-T, a personalised immunotherapy that uses individual patients' tumour antigens to stimulate the immune system against the cancer, was being tested as an add-on to standard therapy with Pfizer's Sutent (sunitinib) and standard care in 462 RCC patients.

While the therapy was well-tolerated, it was "unlikely to demonstrate a statistically significant improvement in overall survival", the trial's primary endpoint, according to a company statement. The result adds to the growing list of failures among cancer vaccine candidates.

Shares in Argos lost two-thirds of their value after the news broke as investors grew concerned about the potentially broader implications on the company's Arcelis individualised immunotherapy platform, which underpins its entire pipeline. An earlier programme in HIV failed to hit the mark in a phase II trial reported in 2015.

"We are extremely disappointed with these results, which included 75% of the targeted events needed to permit the primary analysis and assessment of overall survival in the study," said Argos' CEO Jeff Abbey.

The company said that the trial will remain open while it conducts additional analyses and has discussions with the FDA, adding that it will decide the next steps in the clinical development programme for rocapuldencel-T in the coming weeks.

The company provided no additional information on a conference call, and seems the result has come out of left field as just weeks ago Argos was buoyant about the prospects for rocapuldencel-T, announcing plans to take a lease on 40,000 sq. ft. of manufacturing space in January to support future domestic and international launches of its therapies.

Article by
Phil Taylor

23rd February 2017

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
Bedrock Healthcare Communications

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...